GRANULES INDIA LIMITED

Granules India Limited held its Q1 FY27 earnings conference call on July 21, 2026, where management highlighted a 22% year-on-year revenue growth to INR 1,477 crores, marking the strongest first quarter in the company's history. Gross margins remained healthy at 65.6%, and EBITDA grew 37% to INR 339 crores. Management reported a significant improvement in return on capital to 18% and noted that net debt to EBITDA was nearly zero. The company emphasized its transition to an innovation-led pharmaceutical platform, with complex generics now comprising 50% of finished dosages. Management also discussed ongoing remediation efforts at the Gagillapur facility, stating that they had met FDA requirements and were ready for inspections. Future growth strategies include scaling up the Genome Valley facility and expanding the peptide CDMO platform. The call concluded with a Q&A session addressing various operational and financial queries.

Management emphasized strong financial performance and growth strategies.